Across TCGA pan-cancer cohorts, MYO1C Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYO1C data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher MYO1C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYO1C expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, HNSC, and UCEC are the cancer types where MYO1C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
HNSC	OS	Median	IV	0.064	0.737	<.001	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.028	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	OS	Median	IV	0.130	0.599	.002	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MYO1C tumor-vs-normal RNA expression · all MYO1C data types